| First Author | Yang X | Year | 2019 |
| Journal | Biochem Biophys Res Commun | Volume | 510 |
| Issue | 4 | Pages | 495-500 |
| PubMed ID | 30658852 | Mgi Jnum | J:291536 |
| Mgi Id | MGI:6442401 | Doi | 10.1016/j.bbrc.2019.01.034 |
| Citation | Yang X, et al. (2019) SULT2B1b promotes epithelial-mesenchymal transition through activation of the beta-catenin/MMP7 pathway in hepatocytes. Biochem Biophys Res Commun 510(4):495-500 |
| abstractText | Epithelial-mesenchymal transition (EMT) occurs in the progression of liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). The hydroxysteroid sulfotransferase 2B1b (SULT2B1b) promotes the proliferation of hepatocarcinoma cells both in vitro and in vivo. However, the correlation between SULT2B1b and the EMT in hepatocytes has not yet been addressed. The present study demonstrated that the SULT2B1b overexpression promoted the EMT process in mouse primary hepatocytes in the absence or presence of TGF-beta1 treatment. Moreover, SULT2B1b interference suppressed the EMT and attenuated the migration and invasion abilities of human hepatocarcinoma BEL-7402cells by inhibiting the activation of the beta-catenin/MMP-7 pathway. In summary, SULT2B1b enhanced the EMT of hepatocytes and promoted the migration and invasion abilities of BEL-7402cells by activing the beta-catenin/MMP-7 pathway. Therefore, inhibition of SULT2B1b has therapeutic potential for the treatment of HCC. |
